•  
  •  
  •  
  •  

2026-04-17 23:59:09

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hathway Cable and Datacom Limited Announces Audited Financial Results for FY 2025-26
  • Jio Financial Services Limited Reports Strong Revenue Growth for FY 2025-26
  • Mastek Limited Reports Robust Revenue Growth and Enhanced Profitability for FY 2025-26
  • Bajaj Consumer Care Limited Reports 52% Surge in Annual Net Profit for FY 2025-26
  • National Standard (India) Limited Announces FY 2025-26 Financial Results

Keywords Selected:  USFDA

Stock Report

  • Aurobindo Pharma receives USFDA Approval for Dextromethorphan Polistirex ExtendedRelease Oral Suspension, 30 mg/5 mL (OTC)
  • USFDA inspection at Cipla Ltd's manufacturing facility in Goa, India
  • Morepen Secures Fourth Consecutive USFDA Inspection with Zero Observations
  • Aurobindo Pharma receives USFDA Approval for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL
  • Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Methotrexate Injection USP
  • Indoco Remedies' testing facility completes US FDA PAI
  • Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg
  • Biocon Pharma Ltd receives U.S. FDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States
  • Aurobindo Pharma receives USFDA Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Granules India Limited completes cGMP Audit at its Chantilly Site
  • Marksans Pharma Ltd receives USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)
  • Granules Life Sciences Receives VAI Classification following US FDA Inspection
  • Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
  • Completion of US-FDA Inspection at Unit-IV, Tarapur of Aarti Pharmalabs Limited
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
  • Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
  • Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
  • Eugia Pharma Specialities Ltd receives OAI classification from USFDA for Unit 2

Latest Post

  • Hathway Cable and Datacom Limited Announces Audited Financial Results for FY 2025-26
  • Jio Financial Services Limited Reports Strong Revenue Growth for FY 2025-26
  • Mastek Limited Reports Robust Revenue Growth and Enhanced Profitability for FY 2025-26
  • Bajaj Consumer Care Limited Reports 52% Surge in Annual Net Profit for FY 2025-26
  • National Standard (India) Limited Announces FY 2025-26 Financial Results


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025